Anthony Smithyman
Algemeen Directeur bij Special Phage Holdings Pty Ltd.
Profiel
Anthony Smithyman is the founder of Special Phage Holdings Pty Ltd.
which was founded in 2004.
He held the title of Managing Director at the company.
Currently, he is the Managing Director at Cellabs Pty Ltd.
Dr. Smithyman was a Director at AmpliPhi Biosciences Corp.
from 2012 to 2015.
Dr. Smithyman holds a doctorate degree from the University of Glasgow and an undergraduate degree from the University of St. Andrews.
Actieve functies van Anthony Smithyman
| Bedrijven | Functie | Begin |
|---|---|---|
Special Phage Holdings Pty Ltd.
 Special Phage Holdings Pty Ltd. Medical SpecialtiesHealth Technology Part of Innoviva, Inc., Special Phage Holdings Pty Ltd. operates as a holding Australian company with interests in phage therapy. The company is based in Neutral Bay, Australia. The company was founded by Anthony Smithyman. Anthony Smithyman has been the CEO since incorporation. Special Phage Holdings was acquired by AmpliPhi Australia Pty Ltd. on November 13, 2012 for $6.77 million. | Algemeen Directeur | 23-01-2014 |
Cellabs Pty Ltd.
 Cellabs Pty Ltd. Medical/Nursing ServicesHealth Services Cellabs Pty Ltd. is a boutique diagnostics company based in Sydney that specializes in designing, developing, and manufacturing immunodiagnostic kits for tropical and infectious diseases. The Australian company's focus is on providing accurate and reliable diagnostic solutions to healthcare professionals and patients. The CEO of the private company is Anthony Smithyman. | Algemeen Directeur | - |
Eerdere bekende functies van Anthony Smithyman
| Bedrijven | Functie | Einde |
|---|---|---|
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Directeur/Bestuurslid | 16-04-2015 |
Opleiding van Anthony Smithyman
| University of Glasgow | Doctorate Degree |
| University of St. Andrews | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Cellabs Pty Ltd.
Cellabs Pty Ltd. Medical/Nursing ServicesHealth Services Cellabs Pty Ltd. is a boutique diagnostics company based in Sydney that specializes in designing, developing, and manufacturing immunodiagnostic kits for tropical and infectious diseases. The Australian company's focus is on providing accurate and reliable diagnostic solutions to healthcare professionals and patients. The CEO of the private company is Anthony Smithyman. | Health Services |
Special Phage Holdings Pty Ltd.
Special Phage Holdings Pty Ltd. Medical SpecialtiesHealth Technology Part of Innoviva, Inc., Special Phage Holdings Pty Ltd. operates as a holding Australian company with interests in phage therapy. The company is based in Neutral Bay, Australia. The company was founded by Anthony Smithyman. Anthony Smithyman has been the CEO since incorporation. Special Phage Holdings was acquired by AmpliPhi Australia Pty Ltd. on November 13, 2012 for $6.77 million. | Health Technology |
